Home Cart Sign in  
Chemical Structure| 548-77-6 Chemical Structure| 548-77-6

Structure of Tectorigenin
CAS No.: 548-77-6

Chemical Structure| 548-77-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tectorigenin, a natural product isolated and purified from the rhizomes of Belamcanda chinensis (L.) DC., has antioxidant, anti-inflammatory by inhibiting the induction of COX-2 in the inflammatory cells activities and may be a possible therapeutic agent for leukemia.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tectorigenin

CAS No. :548-77-6
Formula : C16H12O6
M.W : 300.26
SMILES Code : O=C1C(C2=CC=C(O)C=C2)=COC3=C1C(O)=C(OC)C(O)=C3
MDL No. :MFCD00597094

Safety of Tectorigenin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse islet cells 40 μg/ml 24 hours Promote PDX1 expression J Biol Chem. 2020 Sep 11;295(37):12975-12992
Bone marrow mononuclear (BMM) cells 0, 10, 40, 80 µM 1 hour To evaluate the effect of Tectorigenin on RANKL-induced NF-κB signaling activation, results showed that Tectorigenin significantly reduced phosphorylation levels of NF-κB p65 and IκBα. J Cell Mol Med. 2018 Oct;22(10):5121-5131
Rat tendon-derived stem cells (TDSCs) 50 and 100 µM 1-hour pretreatment followed by 24-hours co-culture withours TNF-α To evaluate the inhibitory effects of Tectorigenin on TNF-α-induced inflammation, apoptosis, and ossification in TDSCs. Results showed Tectorigenin suppressed TNF-α-induced upregulation of MMP-3/9/13, COX-2, iNOS, and IL-6 while increasing collagen I and IL-10 expression. Front Cell Dev Biol. 2020 Oct 22;8:568894
PA-induced IR C2C12 cells 10 µg/mL 24 hours TG partially restores GLUT4 levels and improves insulin sensitivity in IR C2C12 cells Int J Biol Sci. 2023 Mar 5;19(5):1579-1596
C2C12 cells 10 µg/mL 24 hours TG enhances GLUT4 expression and promotes glucose uptake Int J Biol Sci. 2023 Mar 5;19(5):1579-1596
LO2 cells 1–200 µM 24 hours To evaluate the effect of Tectorigenin on the viability of LO2 cells, results showed no significant effect on cell viability at concentrations of 1–200 μM Phytother Res. 2019 Apr;33(4):1055-1064
RAW 264.7 cells 1–100 µM 24 hours To evaluate the effect of Tectorigenin on the viability of RAW 264.7 cells, results showed no significant effect on cell viability at concentrations of 1–100 μM Phytother Res. 2019 Apr;33(4):1055-1064
HaCaT human epidermal keratinocytes 0.1, 1, 10 µM 24 hours Tectorigenin significantly reduced MMP-1 levels and increased type 1 collagen levels, thereby preventing collagen degradation. Nutrients. 2018 Dec 17;10(12):1998
HaCaT human epidermal keratinocytes 1, 10 µM 24 hours Tectorigenin significantly inhibited UV-B-induced expression of apoptosis-related proteins such as caspase-3 and Bax, and increased Bcl-2 protein levels. Nutrients. 2018 Dec 17;10(12):1998
HaCaT human epidermal keratinocytes 1, 10 µM 24 hours Tectorigenin significantly increased the expression of anti-oxidative enzymes such as catalase and glutathione. Nutrients. 2018 Dec 17;10(12):1998
HaCaT human epidermal keratinocytes 0.1, 1, 10 µM 24 hours Tectorigenin significantly inhibited UV-B-induced intracellular ROS generation. Nutrients. 2018 Dec 17;10(12):1998
HaCaT human epidermal keratinocytes 0.1, 1, 10 µM 24 hours Tectorigenin at concentrations between 0.1 and 10 µM was not toxic for HaCaT cells and significantly inhibited UV-B-induced cell death. Nutrients. 2018 Dec 17;10(12):1998
RIN-m5F cells 40 μg/ml 24 hours Promote PDX1 expression J Biol Chem. 2020 Sep 11;295(37):12975-12992
INS-1 cells 40 μg/ml 24 hours Promote PDX1 expression and activate ERK signaling pathway J Biol Chem. 2020 Sep 11;295(37):12975-12992
Human liver microsomes 100 µM 30 minutes Investigate the glucuronidation metabolism of Tectorigenin, one metabolite M was detected Molecules. 2022 Jun 26;27(13):4104
RAW264.7 cells 0, 10, 40, 80 µM 4 days To evaluate the preventive effect of Tectorigenin on RANKL-induced osteoclast differentiation, results showed that Tectorigenin reduced osteoclast differentiation in a dose-dependent manner. J Cell Mol Med. 2018 Oct;22(10):5121-5131
Bone marrow mononuclear (BMM) cells 0, 10, 40, 80 µM 4 days To evaluate the preventive effect of Tectorigenin on RANKL-induced osteoclast differentiation, results showed that Tectorigenin reduced osteoclast differentiation in a dose-dependent manner. J Cell Mol Med. 2018 Oct;22(10):5121-5131
RAW264.7 cells 0, 10, 40, 80 µM 48 hours To evaluate the effect of Tectorigenin on RANKL-stimulated osteoclast-specific gene expression, results showed that Tectorigenin down-regulated the expression of TRAP, NFATc1, Cts K, and MMP9. J Cell Mol Med. 2018 Oct;22(10):5121-5131
Bone marrow mononuclear (BMM) cells 0, 10, 40, 80 µM 48 hours To evaluate the effect of Tectorigenin on RANKL-stimulated osteoclast-specific gene expression, results showed that Tectorigenin down-regulated the expression of TRAP, NFATc1, Cts K, and MMP9. J Cell Mol Med. 2018 Oct;22(10):5121-5131
RAW264.7 cells 0, 10, 40, 80 µM 6 hours To evaluate the effect of Tectorigenin on RANKL-induced NF-κB transcriptional activity, results showed that Tectorigenin reduced NF-κB transcriptional activity in a dose-dependent manner. J Cell Mol Med. 2018 Oct;22(10):5121-5131

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Ovariectomy-induced osteoporosis model Abdominal injection 1 mg/kg and 10 mg/kg Every 3 days for 6 weeks To evaluate the effect of Tectorigenin on ovariectomy-induced bone loss, results showed that Tectorigenin significantly reduced bone loss and improved bone microstructure. J Cell Mol Med. 2018 Oct;22(10):5121-5131
C57BL/6J mice HFHSD-induced T2DM mouse model Intraperitoneal injection 10, 20, 40 mg/kg Every other day for 1-2 months Both prophylactic and therapeutic uses of TG significantly ameliorate insulin resistance and hyperglycemia in T2DM mice Int J Biol Sci. 2023 Mar 5;19(5):1579-1596
C57BL/6J mice High-fat/high-sucrose diet-induced diabetes model Intraperitoneal injection 10, 20, 40 mg/kg Once every 2 days for 1 month (treatment) or 3 months (prevention) Ameliorate hyperglycemia and glucose intolerance, inhibit ER stress and islet β-cell apoptosis J Biol Chem. 2020 Sep 11;295(37):12975-12992
Sprague-Dawley rats Achilles tenotomy-induced tendinopathy model Local injection (area between Achilles tendon and skin) 100 μM Once weekly for 8 weeks To assess the therapeutic effect of Tectorigenin on rat tendinopathy. Results demonstrated Tectorigenin improved disordered collagen fiber arrangement, reduced calcification, and decreased MMP-3/13 expression in tendon tissues. Front Cell Dev Biol. 2020 Oct 22;8:568894
C57BL/6J mice LPS/D-GalN-induced fulminant hepatic failure model Intraperitoneal injection 12.5, 25, 50 mg/kg Single dose, observed for 24 hours To evaluate the protective effect of Tectorigenin on LPS/D-GalN-induced fulminant hepatic failure, results showed Tec significantly reduced serum ALT and AST levels, histological injury, apoptosis, and mortality, and suppressed the production of inflammatory cytokines such as TNF-α and IL-6 Phytother Res. 2019 Apr;33(4):1055-1064

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.33mL

0.67mL

0.33mL

16.65mL

3.33mL

1.67mL

33.30mL

6.66mL

3.33mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories